The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immuno-oncology Therapy Market Research Report 2025

Global Immuno-oncology Therapy Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1885485

No of Pages : 101

Ask Your Query
Synopsis
Immuno-oncology therapy is a type of cancer treatment that harnesses the body's immune system to target and destroy cancer cells. It includes therapies such as immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies.
The global Immuno-oncology Therapy market was valued at US$ 1233 million in 2023 and is anticipated to reach US$ 1648.7 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The market for immuno-oncology therapy is driven by the growing interest in personalized and targeted cancer treatments and the need for innovative therapies with fewer side effects. The market's growth is also influenced by the approval of new immuno-oncology drugs and ongoing research in cancer immunotherapy.
This report aims to provide a comprehensive presentation of the global market for Immuno-oncology Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-oncology Therapy.
Report Scope
The Immuno-oncology Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immuno-oncology Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-oncology Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli-Lilly
Roche
GlaxoSmithKline
Janssen Biotech
Merck
Novartis
Pfizer
Sanofi
Spectrum Pharmaceuticals
Takeda
BioNTech SE
Allogene Therapeutics
IMAB-I-Mab Biopharma Co., Ltd.
Arcus Biosciences
Gritstone Oncology
Autolus Therapeutics
Rubius Therapeutics
Segment by Type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Segment by Application
Hospitals
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immuno-oncology Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Immune System Modulators
1.2.5 Cancer Vaccines
1.3 Market by Application
1.3.1 Global Immuno-oncology Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Therapy Market Perspective (2019-2030)
2.2 Immuno-oncology Therapy Growth Trends by Region
2.2.1 Global Immuno-oncology Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Immuno-oncology Therapy Historic Market Size by Region (2019-2024)
2.2.3 Immuno-oncology Therapy Forecasted Market Size by Region (2025-2030)
2.3 Immuno-oncology Therapy Market Dynamics
2.3.1 Immuno-oncology Therapy Industry Trends
2.3.2 Immuno-oncology Therapy Market Drivers
2.3.3 Immuno-oncology Therapy Market Challenges
2.3.4 Immuno-oncology Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immuno-oncology Therapy Players by Revenue
3.1.1 Global Top Immuno-oncology Therapy Players by Revenue (2019-2024)
3.1.2 Global Immuno-oncology Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Immuno-oncology Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immuno-oncology Therapy Revenue
3.4 Global Immuno-oncology Therapy Market Concentration Ratio
3.4.1 Global Immuno-oncology Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Therapy Revenue in 2023
3.5 Immuno-oncology Therapy Key Players Head office and Area Served
3.6 Key Players Immuno-oncology Therapy Product Solution and Service
3.7 Date of Enter into Immuno-oncology Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Therapy Breakdown Data by Type
4.1 Global Immuno-oncology Therapy Historic Market Size by Type (2019-2024)
4.2 Global Immuno-oncology Therapy Forecasted Market Size by Type (2025-2030)
5 Immuno-oncology Therapy Breakdown Data by Application
5.1 Global Immuno-oncology Therapy Historic Market Size by Application (2019-2024)
5.2 Global Immuno-oncology Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Immuno-oncology Therapy Market Size (2019-2030)
6.2 North America Immuno-oncology Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Immuno-oncology Therapy Market Size by Country (2019-2024)
6.4 North America Immuno-oncology Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immuno-oncology Therapy Market Size (2019-2030)
7.2 Europe Immuno-oncology Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Immuno-oncology Therapy Market Size by Country (2019-2024)
7.4 Europe Immuno-oncology Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Therapy Market Size (2019-2030)
8.2 Asia-Pacific Immuno-oncology Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Immuno-oncology Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Immuno-oncology Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immuno-oncology Therapy Market Size (2019-2030)
9.2 Latin America Immuno-oncology Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Immuno-oncology Therapy Market Size by Country (2019-2024)
9.4 Latin America Immuno-oncology Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Therapy Market Size (2019-2030)
10.2 Middle East & Africa Immuno-oncology Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Immuno-oncology Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Immuno-oncology Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Immuno-oncology Therapy Introduction
11.1.4 Amgen Revenue in Immuno-oncology Therapy Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Immuno-oncology Therapy Introduction
11.2.4 AstraZeneca Revenue in Immuno-oncology Therapy Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Introduction
11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Therapy Business (2019-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Eli-Lilly
11.4.1 Eli-Lilly Company Detail
11.4.2 Eli-Lilly Business Overview
11.4.3 Eli-Lilly Immuno-oncology Therapy Introduction
11.4.4 Eli-Lilly Revenue in Immuno-oncology Therapy Business (2019-2024)
11.4.5 Eli-Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Immuno-oncology Therapy Introduction
11.5.4 Roche Revenue in Immuno-oncology Therapy Business (2019-2024)
11.5.5 Roche Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Immuno-oncology Therapy Introduction
11.6.4 GlaxoSmithKline Revenue in Immuno-oncology Therapy Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Janssen Biotech
11.7.1 Janssen Biotech Company Detail
11.7.2 Janssen Biotech Business Overview
11.7.3 Janssen Biotech Immuno-oncology Therapy Introduction
11.7.4 Janssen Biotech Revenue in Immuno-oncology Therapy Business (2019-2024)
11.7.5 Janssen Biotech Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Immuno-oncology Therapy Introduction
11.8.4 Merck Revenue in Immuno-oncology Therapy Business (2019-2024)
11.8.5 Merck Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Immuno-oncology Therapy Introduction
11.9.4 Novartis Revenue in Immuno-oncology Therapy Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Immuno-oncology Therapy Introduction
11.10.4 Pfizer Revenue in Immuno-oncology Therapy Business (2019-2024)
11.10.5 Pfizer Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Detail
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Immuno-oncology Therapy Introduction
11.11.4 Sanofi Revenue in Immuno-oncology Therapy Business (2019-2024)
11.11.5 Sanofi Recent Development
11.12 Spectrum Pharmaceuticals
11.12.1 Spectrum Pharmaceuticals Company Detail
11.12.2 Spectrum Pharmaceuticals Business Overview
11.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Introduction
11.12.4 Spectrum Pharmaceuticals Revenue in Immuno-oncology Therapy Business (2019-2024)
11.12.5 Spectrum Pharmaceuticals Recent Development
11.13 Takeda
11.13.1 Takeda Company Detail
11.13.2 Takeda Business Overview
11.13.3 Takeda Immuno-oncology Therapy Introduction
11.13.4 Takeda Revenue in Immuno-oncology Therapy Business (2019-2024)
11.13.5 Takeda Recent Development
11.14 BioNTech SE
11.14.1 BioNTech SE Company Detail
11.14.2 BioNTech SE Business Overview
11.14.3 BioNTech SE Immuno-oncology Therapy Introduction
11.14.4 BioNTech SE Revenue in Immuno-oncology Therapy Business (2019-2024)
11.14.5 BioNTech SE Recent Development
11.15 Allogene Therapeutics
11.15.1 Allogene Therapeutics Company Detail
11.15.2 Allogene Therapeutics Business Overview
11.15.3 Allogene Therapeutics Immuno-oncology Therapy Introduction
11.15.4 Allogene Therapeutics Revenue in Immuno-oncology Therapy Business (2019-2024)
11.15.5 Allogene Therapeutics Recent Development
11.16 IMAB-I-Mab Biopharma Co., Ltd.
11.16.1 IMAB-I-Mab Biopharma Co., Ltd. Company Detail
11.16.2 IMAB-I-Mab Biopharma Co., Ltd. Business Overview
11.16.3 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Introduction
11.16.4 IMAB-I-Mab Biopharma Co., Ltd. Revenue in Immuno-oncology Therapy Business (2019-2024)
11.16.5 IMAB-I-Mab Biopharma Co., Ltd. Recent Development
11.17 Arcus Biosciences
11.17.1 Arcus Biosciences Company Detail
11.17.2 Arcus Biosciences Business Overview
11.17.3 Arcus Biosciences Immuno-oncology Therapy Introduction
11.17.4 Arcus Biosciences Revenue in Immuno-oncology Therapy Business (2019-2024)
11.17.5 Arcus Biosciences Recent Development
11.18 Gritstone Oncology
11.18.1 Gritstone Oncology Company Detail
11.18.2 Gritstone Oncology Business Overview
11.18.3 Gritstone Oncology Immuno-oncology Therapy Introduction
11.18.4 Gritstone Oncology Revenue in Immuno-oncology Therapy Business (2019-2024)
11.18.5 Gritstone Oncology Recent Development
11.19 Autolus Therapeutics
11.19.1 Autolus Therapeutics Company Detail
11.19.2 Autolus Therapeutics Business Overview
11.19.3 Autolus Therapeutics Immuno-oncology Therapy Introduction
11.19.4 Autolus Therapeutics Revenue in Immuno-oncology Therapy Business (2019-2024)
11.19.5 Autolus Therapeutics Recent Development
11.20 Rubius Therapeutics
11.20.1 Rubius Therapeutics Company Detail
11.20.2 Rubius Therapeutics Business Overview
11.20.3 Rubius Therapeutics Immuno-oncology Therapy Introduction
11.20.4 Rubius Therapeutics Revenue in Immuno-oncology Therapy Business (2019-2024)
11.20.5 Rubius Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock